scholarly journals Evaluation of prescribing pattern of phosphodiesterase-5 inhibitors and assessing effectiveness of sildenafil and tadalafil in patients with erectile dysfunction

2022 ◽  
Vol 8 (4) ◽  
pp. 280-283
Author(s):  
Yatish Byndoor ◽  
Tamilisetti Vidya Sagar ◽  
Sanjay Kumar
Keyword(s):  
Erectile Dysfunction ◽  
Health Care Providers ◽  
Erectile Function ◽  
Phosphodiesterase Inhibitors ◽  
Care Providers ◽  
Pde5 Inhibitors ◽  
Prescribing Pattern ◽  
Therapy Option ◽  
Generic Products ◽  
Phosphodiesterase 5

Several factors may affect identification and treatment of erectile dysfunction by health care providers, this study evaluates prescribing pattern of PDE-5 inhibitors and assess effectiveness of Sildenafil and Tadalafil in patients with erectile dysfunction.This is a descriptive and observational study, observed participants without providing any interventions, after fulfilling inclusion and exclusion criteria, patients were enrolled into study and informed written consent was obtained from all patients, data was obtained from medical records, analysed descriptively. International Index of Erectile Function (IIEF) Questionnaire is used in assessment of erectile dysfunction and treatment outcomes.In our study, 80% of patients were prescribed with phosphodiesterase inhibitors and 20% received nutritional supplements. 80 percent of drugs were prescribed under generic name, subjects treated with Sildenafil/Tadalafil were found to be associated with higher mean scores for questions of International Index of Erectile Function (IIEF). Tadalafil scored high in terms of sexual desire domain.PDE5 inhibitors represent major first-line oral therapy option for men with erectile dysfunction, shift of market from brand to generic products allows more freedom of choice, although multiple reports suggest general equivalency of four major PDE5 inhibitors, tadalafil suggested to be preferable.

scholarly journals Effects of Two Different Dosages of Sildenafil on Patients With Erectile Dysfunction

2015 ◽  
Vol 11 (3) ◽  
pp. 525-530 ◽  
Author(s):  
Hongjun Li ◽  
Gang Bai ◽  
Xinyu Zhang ◽  
Bingbing Shi ◽  
Defeng Liu ◽  
...  
Keyword(s):  
Health Care ◽  
Erectile Dysfunction ◽  
Sexual Intercourse ◽  
Health Care Providers ◽  
Sexual Satisfaction ◽  
Erectile Function ◽  
Care Providers ◽  
Self Assessment ◽  
Sexual Enjoyment

To investigate the effects of two different dosages of sildenafil on patients with erectile dysfunction (ED), a total of 3,674 patients with ED were recruited to answer questionnaires designed specifically for this study. There were 977 patients in the 50 mg group and there were 2,697 patients in the 100 mg group. Both 50 mg and 100 mg of sildenafil therapy increased the ED patients’ average monthly frequency of sexual intercourse, improved erectile function state in self-assessment, and elevated sexual satisfaction and enjoyment. Despite a higher rate of concomitant diseases, patients in the higher dosage of sildenafil group had a better outcome in the average monthly frequency of sexual intercourse and sexual enjoyment compared with those in the lower dosage. Such a study might be helpful for health care providers to choose sildenafil dosage for patients with ED.

scholarly journals Low intensity Extra Corporeal Shock Wave Therapy in Patients with Erectile Dysfunction: Our experience in ACKU

2020 ◽  
Vol 23 (2) ◽  
pp. 176-180
Author(s):  
Md Fazal Naser ◽  
Mahmood Hasan ◽  
Md Waliul Islam ◽  
Tajkera Sultana Chowdhury ◽  
Md Shohrab Hossain
Keyword(s):  
Erectile Dysfunction ◽  
Erectile Function ◽  
Treatment Protocol ◽  
Phosphodiesterase Inhibitors ◽  
Shockwave Therapy ◽  
Low Intensity ◽  
Weekly Session ◽  
Linear Probe ◽  
Study Population ◽  
Energy Flux Density

Introduction: Oral 5-phosphodiesterase inhibitors (PDE5-I) is the main therapeutical options in erectile dysfunction (ED). It shows good results, but non-responders lack other effective options and its effect is also not long lasting. Since last few years, low-intensity extracorporeal shockwave therapy (Li-ESWT) in the corpora cavernosa showing promising results. This article presents our early experiences in Advanced Center of Kidney disease and Urology (ACKU) with the aim to evaluate clinical efficacy of Li-ESWT. Materials and methods: Thirty four patients with ED were prospectively included in the study during the period of January 2018 to Jun 2019.Treatment was performed using the PiezoWave2 (Richard Wolf, Germany) device with a linear probe. Treatment protocol included a weekly session for four weeks. Each session delivered 2000 shocks on the perineum plus 4000 shocks on dorsum penis with an energy flux density (EFD) of 0.160 mJ/mm2. Every patient has been re-evaluated 1.5 and 3 months after the last session. Pre- and post-procedure International Index Erectile Function – Erectile function domain (IIEF-EF) score, Erection Hardness Score (EHS) and Global Assessment Questionnaire-Question 1 (GAQ-Q1) answers were obtained. Results: Mean age of the study population was 39.4 (±12.9) years, 35.29% diabetic, 20.59% with hypertension and 55.85% smokers. Mean baseline IIEF-EF was 14.6, at 6 week post LiSWT was 16.4 (p >0.05) and at 3 months post LiSWT was 19.2 (p < 0.05). EHS was significantly improved at 3 month in comparison to baseline (p<0.05). 20.59% patients answered positively to GAQ-Q1 at 6 week and 61.76% at 3 months. IIEF-EF score change of >5 and increase of EHS >2 were observed in 62.88% and 70.59% study subjects respectively. Conclusions: Li-ESWT is a safe, harmless and repeatable treatment tool for ED with good outcomes reported. Bangladesh Journal of Urology, Vol. 23, No. 2, July 2020 p.176-180

scholarly journals Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors

2017 ◽  
Vol 12 (1) ◽  
pp. 1934578X1701200 ◽  
Author(s):  
Prapapan Temkitthawon ◽  
Kanokwan Changwichit ◽  
Nantaka Khorana ◽  
Jarupa Viyoch ◽  
Khanit Suwanborirux ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Erectile Dysfunction ◽  
Chemical Constituents ◽  
Pde5 Inhibitor ◽  
Pde5 Inhibitors ◽  
New Class ◽  
Phosphodiesterase 5 Inhibitors ◽  
Phosphodiesterase 5

Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon (E.C. Parish & Rchb. f) Hook. f A new phenanthrene, 9,10-dihydro-4-(4′-hydroxybenzyl)-2,5-dimethoxyphenanthrene-1,7-diol (1) and three known phenanthrenes i.e., 1-(4′-hydroxybenzyl)-4,8-dimethoxyphenanthrene-2,7-diol (2), (9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol (3) and 1,5,7-trimethoxyphenanthrene-2,6-diol) (4) were isolated. Among these, 2 was the most potent PDE5 inhibitor (IC50 =1.67±0.54 μM) evaluated by the [3H]cGMP radioassay method, whereas 1 showed mild activity (IC50 = 62.3±3.3 μM). Their inhibitory selectivities against PDE5 over PDE6 were also studied. This study suggests phenanthrenes as a new class of PDE5 inhibitors.

scholarly journals Association Between Periodontal Disease and Erectile Dysfunction: A Systematic Review

2016 ◽  
Vol 12 (2) ◽  
pp. 338-346 ◽  
Author(s):  
Sergio Varela Kellesarian ◽  
Tammy Varela Kellesarian ◽  
Vanessa Ros Malignaggi ◽  
Mansour Al-Askar ◽  
Alexis Ghanem ◽  
...  
Keyword(s):  
Systematic Review ◽  
Erectile Dysfunction ◽  
Periodontal Disease ◽  
Health Care Providers ◽  
Experimental Studies ◽  
Positive Association ◽  
Care Providers ◽  
Letters To The Editor ◽  
Cross Sectional ◽  
Pertinent Data

A limited number of studies have reported an association between erectile dysfunction (ED) and chronic periodontitis (CP). The aim of the present study is to assess the association between CP and ED through a systematic review of published literature. To address the focused question, “Is there a relationship between ED and CP?” indexed databases were searched till December 2015 using various key words “erectile dysfunction,” “periodontal disease,” “periodontitis,” “dental infection,” and “impotence.” Letters to the editor, commentaries, historic reviews, and experimental studies were excluded. The pattern of the present systematic review was customized to primarily summarize the pertinent data. Nine studies were included. Seven studies had a cross-sectional design and two studies were randomized control trials. The number of study participants ranged between 53 and 513,258 individuals with age ranging between 20 years and 85 years (median age ranging between 34.9 ± 4.9 years and 50.9 ± 16.6 years). In all studies, a positive relationship between CP and ED was reported. In four studies, odds ratio were reported, ranging between 1.53 and 3.35. From the literature reviewed, there seems to be a positive association between ED and CP; however, further well-designed controlled clinical trials are needed in this regard. It is emphasized that physicians should refer patients with ED to oral health care providers for a comprehensive oral evaluation and treatment.

scholarly journals Analysis of prescribing pattern of antimicrobial agents and its rationality in tertiary care rural setup of Central India

2017 ◽  
Vol 6 (9) ◽  
pp. 2289
Author(s):  
Nitin D. Pise ◽  
Swapnil B. Kaikade
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Antimicrobial Agents ◽  
Antibiotic Prescription ◽  
Tertiary Care ◽  
Resistance Pattern ◽  
Care Providers ◽  
Prescribing Pattern ◽  
Cross Sectional ◽  
Resistant Strains

Background: Antimicrobial agents are most commonly prescribed drug and share major cost of the treatment. Excessive and inappropriate use of antimicrobial has become a global problem, resulting not only in substantial economic burden on healthcare system but also in contributing to the selective pressure favoring the emergence of antibiotic-resistant microorganisms. Antimicrobial agents which one uses for prophylactic, empiric and therapeutic purposes, depends upon the local epidemiology of infectious diseases, microbiology and resistance pattern as well as local clinical experience. Rational use of antibiotics is one of the most important way of preventing development of resistant strains to these drugs. However, for this, the health care providers should be aware of the available antibiotic prescription guidelines and should strictly adhere to it. Also, they should be updated of emerging resistant strains. Though the strict guidelines are available for the use of antibiotics, there are differences in level of knowledge and approach to antibiotic prescription among professional health care providers.Methods: The present cross sectional study was carried out in A.V.B.R. Teaching Hospital by collecting data from admitted patient’s case paper, tabulated in seven groups of diseases and different groups of antimicrobial agents prescribed.Results: Penicillin and quinolone group of antimicrobials show maximum use whereas sensitivity found more in cephalosporins and quinolone group of antimicrobials.Conclusions: It was found that Cephalosporins (3rd Gen.) are the most commonly prescribed antimicrobial agents followed by aminoglycosides (Gentamicin) and Fluroquinolones (Ciprofloxacin).

Phosphodiesterase 5 Inhibitors for Erectile Dysfunction

2005 ◽  
Vol 39 (7-8) ◽  
pp. 1286-1295 ◽  
Author(s):  
Stephen M Setter ◽  
Jason L Iltz ◽  
Jack E Fincham ◽  
R Keith Campbell ◽  
Danial E Baker
Keyword(s):  
Clinical Trial ◽  
Erectile Dysfunction ◽  
Data Extraction ◽  
Pde5 Inhibitor ◽  
Clinical Trial Data ◽  
Research Review ◽  
Pde5 Inhibitors ◽  
Search Terms ◽  
Review Articles ◽  
Phosphodiesterase 5

OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED). DATA SOURCES Primary research and review articles were identified through a search of ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts (1990–August 2004). The following search terms were used in the Medicine Dentistry and Pharmacology, Toxicology, and Pharmaceutical Sciences subcategories: phosphodiesterase 5 inhibitor, PDE5 inhibitor, erectile dysfunction, sildenafil, vardenafil, tadalafil, prostatectomy, and diabetes. Web of Science (1990–August 2004) was used to search for additional abstracts using the same search terms as above. The package inserts for sildenafil, vardenafil, and tadalafil were also consulted. STUDY SELECTION AND DATA EXTRACTION All identified research, review articles, and abstracts were assessed for relevance, and all relevant information was included. Priority was given to the primary medical literature and clinical trial reports. DATA SYNTHESIS ED is a common disorder in males with increased prevalence associated with age and presence of cardiovascular disease, prostatectomy, or diabetes mellitus. Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors currently available for treatment of ED. Their pharmacology and pharmacokinetics vary slightly, but with potentially important clinical differences in duration of activity; all have similar clinical efficacy and adverse effect profiles in patients with ED of various causes. CONCLUSIONS Sildenafil, vardenafil, and tadalafil are safe and effective PDE5 inhibitors for the treatment of ED.

Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature

2006 ◽  
Vol 10 (3) ◽  
pp. 128-130 ◽  
Author(s):  
Renee A. Beach ◽  
Frank Murphy ◽  
Ronald B. Vender
Keyword(s):  
Erectile Dysfunction ◽  
Drug Eruption ◽  
Pde5 Inhibitor ◽  
Sexual Performance ◽  
Pde5 Inhibitors ◽  
Fixed Drug Eruption ◽  
The Past ◽  
Fixed Drug ◽  
Performance Satisfaction ◽  
Phosphodiesterase 5

Background: In the past 9 years, drugs for erectile dysfunction (ED) have been increasingly prescribed for men with erectile difficulty. These drugs, phosphodiesterase 5 (PDE5) inhibitors, help men with ED obtain and sustain an erection, improving both sexual function and sexual performance satisfaction. However, these drugs contain side effects. Objectives: A 56-year-old man developed an erythematous, circle-shaped lesion on his penis. The lesion was recurrent, with evidence of desquamation. The aim was to determine the source of the recurrent lesion based on its morphology and the patient's verbal history. Results: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made. He was not rechallenged with the drug. However, he experienced a subsequent recurrence of the eruption on inadvertent rechallenge. Conclusions: We believe this case to be the first report of this type of reaction owing to tadalafil. Therefore, fixed drug eruption is a newly observable side effect of this drug.

scholarly journals Evaluation of prescribing pattern of antidiabetic drugs in medicine outpatient clinic of a tertiary care teaching hospital

2017 ◽  
Vol 6 (12) ◽  
pp. 2843
Author(s):  
Vineet Kumar ◽  
Manmeet Topno ◽  
Manju Gari ◽  
Megha Bansal ◽  
Kishor Chakraborty ◽  
...  
Keyword(s):  
Drug Utilization ◽  
Health Care Providers ◽  
Outpatient Clinic ◽  
Tertiary Care ◽  
Diabetic Patients ◽  
Care Hospital ◽  
Care Providers ◽  
Type 2 Diabetic Patients ◽  
Prescribing Pattern ◽  
Cross Sectional

Background: Diabetes is rapidly gaining the status of a potential epidemic in India with more than 62 million diabetics currently diagnosed with the disease. Drug utilization studies are of paramount importance for the optimization of drug therapy and promote rational drug use among health care providers. The aim of this study was to investigate the drug utilization pattern in type-2 diabetic patients. The objective of the study was to analyse the prescribing pattern of anti-diabetic drugs in a tertiary care hospital.Methods: A prospective, cross-sectional study was carried out in medicine outpatient clinic of tertiary care hospital, RIMS Ranchi for a period of 7 months. The data was analysed using WHO core indicators and Microsoft Excel 2013.Results: The total number of encounters surveyed was 94. Avg no of drugs per prescription was 3.04. Percentage of drugs prescribed by generic name was found to be 34.2%. Percentage of prescriptions was a) with antibiotics was 27.6%, b) with insulin was 14.89%, c) from essential drugs list 44.05%. Most common co morbid disease was found to be hypertension present in 27.6% cases.Most commonly use drug was found to be metformin followed by glimepiride.Conclusions: Implementation of WHO core prescribing indicators by the prescribers would help us to reduce the cost, to recognize and prevent potentially dangerous drug- drug interaction and antibiotic resistance.

Sign in / Sign up

Export Citation Format

Share Document